Provided by Tiger Trade Technology Pte. Ltd.

HARBOR HEALTH CARE ETF

33.06
-0.7100-2.10%
Volume:4K
Turnover:120.06K
Market Cap:42.15M
PE:- -
High:33.72
Open:33.72
Low:32.84
Close:33.77
52wk High:35.61
52wk Low:27.50
Shares:1.28M
Float Shares:1.28M
Volume Ratio:0.56
T/O Rate:0.28%
Dividend:0.08
Dividend Rate:0.23%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Aug 31

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Aug 31

Ascendis and Biomarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to Yuviwel® (Navepegritide)

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Aug 31

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
Aug 31

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
Aug 31

Ascendis Pharma Price Target Maintained with a $345.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

TIPRANKS
·
Aug 31

Biomarin Pharmaceutical Shares up 5.6% Premarket After Co Announces Global Settlement with Ascendis Pharma

THOMSON REUTERS
·
Aug 31

BioMarin Settles Patent Lawsuits With Ascendis Pharma Over Yuviwel

MT Newswires Live
·
Aug 31

Biomarin Pharmaceutical - to Dismiss Itc Investigation; All Ip Claims Resolved Including Litigation in Multiple Countries

THOMSON REUTERS
·
Aug 31

Will Japan’s First IMCIVREE Approval in Hypothalamic Obesity Change Rhythm Pharmaceuticals’ (RYTM) Narrative

Simply Wall St.
·
Aug 31

Protagonist announces Takeda received U.S. FDA approval for MIMRYLO

TIPRANKS
·
Aug 31

Gilead (GILD) Stock Stays Cheap After A 143% Five Year Run

Simply Wall St.
·
Aug 30

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Takeda Wins FDA Nod for First-in-Class Polycythemia Vera Therapy MIMRYLO

TIPRANKS
·
Aug 29

Takeda receives FDA approval of NDA for Mimrylo

TIPRANKS
·
Aug 29

India's GLP-1 Weight-Loss Drugs Stall at $14 Monthly Despite High Diabetes Rates

Deep News
·
Aug 29

Gilead Sciences Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29